We are live on ! Find out more
VBIO

Valion Bio

7 hedge funds and large institutions have $567K invested in Valion Bio in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

204% more capital invested

Capital invested by funds: $187K → $567K (+$380K)

75% more funds holding

Funds holding: 47 (+3)

7.35% more ownership

Funds ownership: 5.12%12.46% (+7.3%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
3
Increased
Reduced
3
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
LM
Lasry Marc
+$351K
2
DS
DRW Securities
Illinois
+$186K
3
Citigroup
Citigroup
New York
+$4.93K
Name Holding Trade Value Shares
Change
Change in
Stake
LM
1
Lasry Marc
$294K +$351K +101,638 New
DS
2
DRW Securities
Illinois
$156K +$186K +53,935 New
MG
3
Marex Group
$111K -$3.07K -890 -2%
Citigroup
4
Citigroup
New York
$4.13K +$4.93K +1,430 New
UBS Group
5
UBS Group
Switzerland
$2.31K -$16.7K -4,852 -86%
SS
6
SBI Securities
Japan
$46
Bank of America
7
Bank of America
North Carolina
$23 -$3 -1 -11%

VBIO Hedge Fund Activity: Q3 2025 in Review

7 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q3 2025, worth a combined $567K — up 204% from $187K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new VBIO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 3 trimmed.

The largest buyer was Lasry Marc, opening a new position worth an estimated $351K. The largest seller was UBS Group, cutting an estimated $16.7K.

  • 7 institutional investors held Valion Bio (VBIO) as of Q3 2025, up from 4 in Q2 2025.
  • Funds reported $567K of Valion Bio stock for Q3 2025, up 204% quarter-over-quarter.
  • 3 funds opened new Valion Bio positions in Q3 2025 and 0 closed out, a net change of +3 holders.
  • The largest Valion Bio buyer in Q3 2025 was Lasry Marc, an estimated $351K added.
  • The largest Valion Bio seller in Q3 2025 was UBS Group, an estimated $16.7K sold.

Based on aggregated 13F filings for Q3 2025.